Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)

View Full Paper
Ask AI
Bookmark
Share

Authors

QYQingsong YinSJSongfu Jiang

Discussion

Loading...

Member takes

Overview

Phase 1 trial suggests GT919 + dexamethasone improves outcomes in relapsed refractory multiple myeloma, indicating potential as a new treatment.

Key Points

  • This study aims to evaluate the safety and preliminary efficacy of GT919 in patients with relapsed or refractory multiple myeloma.
  • Open-label, multicenter Phase I study
  • Dose escalation and expansion cohorts
  • GT919 administered with dexamethasone
  • Safety and pharmacodynamic assessments
  • Inclusion of R/R MM patients refractory to prior therapies.
  • No dose-limiting toxicities observed.
  • Overall response rate of 36% in evaluable patients.
  • Significant pharmacokinetics and pharmacodynamics support efficacy and safety profile.
  • Median progression-free survival not reached, longest >20 months.

Cite This Study

Yin et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df52https://doi.org/10.1182/blood-2025-2278
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma2025 · 3 citations
  2. 2Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study2025
  3. 3Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 12025 · 2 citations
  4. 4Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma2025
  5. 5Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study2025 · 11 citations